- Home
- Automated
- List of product information
- INFANRIX IPV+HIB VACCINE [SIN10988P]
INFANRIX IPV+HIB VACCINE [SIN10988P]
Active ingredients: INFANRIX IPV+HIB VACCINE
Last updated 26 October 2025
On this page
Product Info
INFANRIX IPV+HIB VACCINE
[SIN10988P]
Product information
Active Ingredient and Strength | DIPHTHERIA TOXOID (D) - MIN 30 INTERNATIONAL UNITS/0.5 ML |
Dosage Form | INJECTION |
Manufacturer and Country | GLAXOSMITHKLINE BIOLOGICALS - FRANCE |
Registration Number | SIN10988P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07CA06 |
Indications
Infanrix-IPV+Hib is indicated for active immunisation in infants from the age of 2 months against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b.
Infanrix-IPV+Hib is also indicated as a booster dose for children who have previously been immunised with diphtheria, tetanus, pertussis (DTP), polio and Hib antigens.
Infanrix-IPV+Hib does not protect against diseases caused by other types of Haemophilus influenzae nor against meningitis caused by other organisms.
Dosage and Administration
Posology
The primary vaccination schedule consists of three doses in the first 6 months of life and can start from the age of 2 months. An interval of at least 1 month should be maintained between subsequent doses.
A booster dose is recommended in the second year of life, with an interval of at least 6 months after completion of primary vaccination schedule.
Method of administration
Infanrix-IPV+Hib is for deep intramuscular injection, in the anterolateral thigh.
It is preferable that each subsequent dose is given at alternate sites.
Infanrix-IPV+Hib should be administered with caution to subjects with thrombocytopenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects. Firm pressure should be applied to the injection site (without rubbing) for at least two minutes.
Contraindications
Infanrix-IPV+Hib should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of diphtheria, tetanus, pertussis, inactivated polio or Hib vaccines.
Infanrix-IPV+Hib is contraindicated if the child has experienced an encephalopathy of unknown aetiology, occurring within 7 days following previous vaccination with pertussis-containing vaccine.